Implications of Dose and Response to Long-Term Granulocyte Colony Stimulating Factor (G-CSF) in a Patient with Severe Congenital Neutropenia

Description

Rosenberg et al evaluated patients with severe congenital neutropenia who received long-term therapy with granulocyte colony stimulating factor (G-CSF). A patient who responds poorly to higher doses is at greater risk for a poor outcome. The authors are from the National Cancer Institute (NCI) and multiple institutions in the United States, Canada, Aurstralia and Europe.

Parameters:

(1) dose of G-CSF relative to median dose

(2) absolute neutrophil count at 6 to 18 months (relative response to G-CSF)

Parameter	Finding	Points
dose relative to median	< 8 µg/kg/d	0
	>= 8 µg/kg/d	1
absolute neutrophil count	>= 2,188 per µL	0
	< 2,188 per µL	1

total score =

= SUM(points for the 2 parameters)

Interpretation:

• minimum score: 0

• maximum score: 2

• The higher the score the greater the risk of myelodysplasia with or without AML and the risk of dying from sepsis.

• A patient with both risk factors may benefit from an early hematopoietic stem cell transplant.

To read more or access our algorithms and calculators, please log in or register.

Implications of Dose and Response to Long-Term Granulocyte Colony Stimulating Factor (G-CSF) in a Patient with Severe Congenital Neutropenia

Description

Specialty